1 2450 152 EPIGENETIC SUPPRESSION OF LIVER X RECEPTOR BETA IN ANTERIOR CINGULATE CORTEX BY HDAC5 DRIVES CFA-INDUCED CHRONIC INFLAMMATORY PAIN. BACKGROUND: LIVER X RECEPTORS (LXRS), INCLUDING LXRALPHA AND LXRBETA, ARE KEY REGULATORS OF TRANSCRIPTIONAL PROGRAMS FOR BOTH CHOLESTEROL HOMEOSTASIS AND INFLAMMATION IN THE BRAIN. HERE, THE MODES OF ACTION OF LXRS AND THE EPIGENETIC MECHANISMS REGULATING LXRBETA EXPRESSION IN ANTERIOR CINGULATE CORTEX (ACC) OF CHRONIC INFLAMMATORY PAIN (CIP) ARE INVESTIGATED. METHODS: THE DEFICIT OF LXR ISOFORM AND ANALGESIC EFFECT OF LXR ACTIVATION BY GW3965 WERE EVALUATED USING THE MOUSE MODEL OF CIP INDUCED BY HINDPAW INJECTION OF COMPLETE FREUND'S ADJUVANT (CFA). THE MECHANISMS INVOLVED IN GW-MEDIATED ANALGESIC EFFECTS WERE ANALYZED WITH IMMUNOHISTOCHEMICAL METHODS, ELISA, CO-IMMUNOPRECIPITATION (CO-IP), WESTERN BLOT, AND ELECTROPHYSIOLOGICAL RECORDING. THE EPIGENETIC REGULATION OF LXRBETA EXPRESSION WAS INVESTIGATED BY CHROMATIN IMMUNOPRECIPITATION, QUANTITATIVE REAL-TIME PCR, AND SEQUENCING. RESULTS: WE REVEALED THAT CFA INSULT LED TO LXRBETA REDUCTION IN ACC, WHICH WAS ASSOCIATED WITH UPREGULATED EXPRESSION OF HISTONE DEACETYLASE 5 (HDAC5), AND KNOCKDOWN OF LXRBETA BY SHRNA LED TO THERMAL HYPERALGESIA. CO-IP SHOWED THAT LXRBETA INTERACTED WITH NF-KAPPAB P65 PHYSICALLY. LXRBETA ACTIVATION BY GW3965 EXERTED ANALGESIC EFFECTS BY INHIBITING THE NUCLEAR TRANSLOCATION OF NF-KAPPAB, REDUCING THE PHOSPHORYLATION OF MITOGEN-ACTIVATED PROTEIN KINASES (MAPKS) IN ACC, AND DECREASING THE PROMOTED INPUT-OUTPUT AND ENHANCED MEPSC FREQUENCY IN ACC NEURONS AFTER CFA EXPOSURE. IN VITRO EXPERIMENTS CONFIRMED THAT HDAC5 TRIGGERED HISTONE DEACETYLATION ON THE PROMOTER REGION OF LXRBETA, RESULTING IN DOWNREGULATION OF LXRBETA TRANSCRIPTION. CONCLUSION: THESE FINDINGS HIGHLIGHT AN EPIGENETIC MECHANISM UNDERLYING LXRBETA DEFICITS LINKED TO CIP, AND LXRBETA ACTIVATION MAY REPRESENT A POTENTIAL NOVEL TARGET FOR THE TREATMENT OF CIP WITH AN ALTERATION IN INFLAMMATION RESPONSES AND SYNAPTIC TRANSMISSION IN ACC. 2019 2 1318 44 DEMETHYLATION OF G-PROTEIN-COUPLED RECEPTOR 151 PROMOTER FACILITATES THE BINDING OF KRUPPEL-LIKE FACTOR 5 AND ENHANCES NEUROPATHIC PAIN AFTER NERVE INJURY IN MICE. G-PROTEIN-COUPLED RECEPTORS ARE CONSIDERED TO BE CELL-SURFACE SENSORS OF EXTRACELLULAR SIGNALS, THEREBY HAVING A CRUCIAL ROLE IN SIGNAL TRANSDUCTION AND BEING THE MOST FRUITFUL TARGETS FOR DRUG DISCOVERY. G-PROTEIN-COUPLED RECEPTOR 151 (GPR151) WAS REPORTED TO BE EXPRESSED SPECIFICALLY IN THE HABENULAR AREA. HERE WE REPORT THE EXPRESSION AND THE EPIGENETIC REGULATION OF GRP151 IN THE SPINAL CORD AFTER SPINAL NERVE LIGATION (SNL) AND THE CONTRIBUTION OF GPR151 TO NEUROPATHIC PAIN IN MALE MICE. SNL DRAMATICALLY INCREASED GPR151 EXPRESSION IN SPINAL NEURONS. GPR151 MUTATION OR SPINAL INHIBITION BY SHRNA ALLEVIATED SNL-INDUCED MECHANICAL ALLODYNIA AND HEAT HYPERALGESIA. INTERESTINGLY, THE CPG ISLAND IN THE GPR151 GENE PROMOTER REGION WAS DEMETHYLATED, THE EXPRESSION OF DNA METHYLTRANSFERASE 3B (DNMT3B) WAS DECREASED, AND THE BINDING OF DNMT3B WITH GPR151 PROMOTER WAS REDUCED AFTER SNL. OVEREXPRESSION OF DNMT3B IN THE SPINAL CORD DECREASED GPR151 EXPRESSION AND ATTENUATED SNL-INDUCED NEUROPATHIC PAIN. FURTHERMORE, KRUPPEL-LIKE FACTOR 5 (KLF5), A TRANSCRIPTIONAL FACTOR OF THE KLF FAMILY, WAS UPREGULATED IN SPINAL NEURONS, AND THE BINDING AFFINITY OF KLF5 WITH GPR151 PROMOTER WAS INCREASED AFTER SNL. INHIBITION OF KLF5 REDUCED GPR151 EXPRESSION AND ATTENUATED SNL-INDUCED PAIN HYPERSENSITIVITY. FURTHER MRNA MICROARRAY ANALYSIS REVEALED THAT MUTATION OF GPR151 REDUCED THE EXPRESSION OF A VARIETY OF PAIN-RELATED GENES IN RESPONSE TO SNL, ESPECIALLY MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) SIGNALING PATHWAY-ASSOCIATED GENES. THIS STUDY REVEALS THAT GPR151, INCREASED BY DNA DEMETHYLATION AND THE ENHANCED INTERACTION WITH KLF5, CONTRIBUTES TO THE MAINTENANCE OF NEUROPATHIC PAIN VIA INCREASING MAPK PATHWAY-RELATED GENE EXPRESSION.SIGNIFICANCE STATEMENT G-PROTEIN-COUPLED RECEPTORS (GPCRS) ARE TARGETS OF VARIOUS CLINICALLY APPROVED DRUGS. HERE WE REPORT THAT SNL INCREASED GPR151 EXPRESSION IN THE SPINAL CORD, AND MUTATION OR INHIBITION OF GPR151 ALLEVIATED SNL-INDUCED NEUROPATHIC PAIN. IN ADDITION, SNL DOWNREGULATED THE EXPRESSION OF DNMT3B, WHICH CAUSED DEMETHYLATION OF GPR151 GENE PROMOTER, FACILITATED THE BINDING OF TRANSCRIPTIONAL FACTOR KLF5 WITH THE GPR151 PROMOTER, AND FURTHER INCREASED GPR151 EXPRESSION IN SPINAL NEURONS. THE INCREASED GPR151 MAY CONTRIBUTE TO THE PATHOGENESIS OF NEUROPATHIC PAIN VIA ACTIVATING MAPK SIGNALING AND INCREASING PAIN-RELATED GENE EXPRESSION. OUR STUDY REVEALS AN EPIGENETIC MECHANISM UNDERLYING GPR151 EXPRESSION AND SUGGESTS THAT TARGETING GPR151 MAY OFFER A NEW STRATEGY FOR THE TREATMENT OF NEUROPATHIC PAIN. 2018 3 1298 36 DECREASED NUCLEAR RECEPTOR ACTIVITY AND EPIGENETIC MODULATION ASSOCIATES WITH DOWN-REGULATION OF HEPATIC DRUG-METABOLIZING ENZYMES IN CHRONIC KIDNEY DISEASE. PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) REQUIRE MANY MEDICATIONS. CYP2C AND CYP3A DRUG-METABOLIZING ENZYMES PLAY A CRITICAL ROLE IN DETERMINING THE PHARMACOKINETICS OF THE MAJORITY OF PRESCRIBED MEDICATIONS. THESE ENZYMES ARE TRANSCRIPTIONALLY REGULATED BY THE NUCLEAR RECEPTORS PREGNANE X RECEPTOR (PXR) AND HEPATIC NUCLEAR FACTOR 4ALPHA (HNF-4ALPHA). EXPRESSION OF CYP2C AND CYP3A IS DECREASED IN CKD; HOWEVER, THE MECHANISMS BY WHICH THIS OCCURS IS UNKNOWN. WE INDUCED CKD IN RATS BY 5/6 NEPHRECTOMY AND USED CHROMATIN IMMUNOPRECIPITATION (CHIP) TO DETERMINE NUCLEAR RECEPTOR- AND EPIGENETIC ALTERATION-MEDIATED DIFFERENCES IN THE PROMOTER REGION OF THE CYP2C AND CYP3A GENES. RNA POLYMERASE II AND HNF-4ALPHA BINDING WAS DECREASED 76 AND 57% IN THE CYP2C11 PROMOTOR AND 71 AND 77% IN THE CYP3A2 PROMOTER, RESPECTIVELY (P<0.05). CHIP ALSO REVEALED A 57% DECREASE IN PXR BINDING TO THE CYP3A2 PROMOTER IN CKD RATS (P<0.05). THE DECREASE IN PXR AND HNF-4ALPHA BINDING WAS ACCOMPANIED BY DIMINISHED HISTONE 4 ACETYLATION IN THE CYP3A2 PROMOTER (48%) AND HISTONE 3 ACETYLATION IN THE CYP2C11 (77%) AND CYP3A2 (77%) PROMOTER LOCI FOR NUCLEAR RECEPTOR ACTIVATION (P<0.05). THIS STUDY SUGGESTS THAT DECREASED NUCLEAR RECEPTOR BINDING AND HISTONE ACETYLATION MAY CONTRIBUTE TO THE MECHANISM OF DRUG-METABOLIZING ENZYME DOWN-REGULATION AND ALTERED PHARMACOKINETICS IN CKD. 2014 4 3128 50 GIPC-REGULATED IGFBP-3 PROMOTES HSC MIGRATION IN VITRO AND PORTAL HYPERTENSION IN VIVO THROUGH A BETA1-INTEGRIN PATHWAY. BACKGROUND & AIMS: TRANSFORMING GROWTH FACTOR (TGF-BETA)-INDUCED ACTIVATION OF QUIESCENT HEPATIC STELLATE CELLS (HSCS) AND THEIR TRANSFORMATION TO MYOFIBROBLASTS IS A KEY EVENT IN LIVER FIBROSIS AND PORTAL HYPERTENSION. GIPC (ALSO REFERRED TO AS SYNECTIN) IS A DOWNSTREAM SIGNAL ACTIVATION MOLECULE OF TGF-BETA AND OTHER RECEPTORS. IN THIS STUDY, WE SOUGHT TO IDENTIFY NOVEL GENES TARGETED BY TGF-BETA AND GIPC AND ELUCIDATE IF AND HOW THEY MAY CONTRIBUTE TO LIVER FIBROSIS. METHODS: WE PERFORMED SEQUENTIAL MESSENGER RNA SEQUENCING ANALYSIS ON TGF-BETA-STIMULATED HSCS AND THEN ON TGF-BETA-STIMULATED HSCS IN THE PRESENCE AND ABSENCE OF GIPC ALSO REFERRED TO AS SYNECTIN (GIPC) KNOCKDOWN. INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 (IGFBP-3) TRANSPORT PROTEIN EMERGED AS A TOP ACTIVATION TARGET OF BOTH TGF-BETA AND GIPC. QUANTITATIVE POLYMERASE CHAIN REACTION, ENZYME-LINKED IMMUNOSORBENT ASSAY, TARGETED CHROMATIN IMMUNOPRECIPITATION, AND WESTERN BLOT ANALYSIS WERE DONE FOR FURTHER CONFIRMATION. RESULTS: IGFBP-3, AN INSULIN GROWTH FACTOR TRANSPORT PROTEIN, EMERGED AS A TOP ACTIVATION TARGET OF BOTH TGF-BETA AND GIPC, WHICH WAS CONFIRMED BY QUANTITATIVE POLYMERASE CHAIN REACTION, ENZYME-LINKED IMMUNOSORBENT ASSAY, AND WESTERN BLOT ANALYSIS. TARGETED CHROMATIN IMMUNOPRECIPITATION SHOWED THAT GIPC INCREASES THE HISTONE 3 LYSINE 27 (H3K27) ACETYLATION ACTIVATING MARK AND CONCURRENTLY DECREASES THE H3K27 INHIBITORY TRIMETHYLATION (H3K27M3) MARK, PROVIDING AN EPIGENETIC CORRELATE TO THE GENE REGULATION CHANGES. IN VIVO, GLOBAL KNOCKOUT OF IGFBP-3 MICE RESULTED IN ATTENUATION OF HSC ACTIVATION MARKERS AND ATTENUATION OF PORTAL PRESSURE IN RESPONSE TO CHRONIC LIVER INJURY MODELS. ANALYSIS OF SERUM LEVELS FROM CIRRHOTIC PATIENTS ALSO SHOWED AN IGFBP-3 INCREASE OF MORE THAN 2-FOLD COMPARED WITH HEALTHY CONTROLS. FINALLY, IN VITRO MECHANISM STUDIES SHOWED THAT IGFBP-3 PROMOTES HSC MIGRATION THROUGH INTEGRIN-DEPENDENT PHOSPHORYLATION OF PROTEIN KINASE B. CONCLUSIONS: TGF-BETA UP-REGULATES IGFBP-3 THROUGH GIPC, LEADING TO INCREASED HSC MIGRATION IN VITRO AND PROMOTES PORTAL HYPERTENSION IN VIVO. THESE STUDIES SUPPORT THE ROLE OF IGFBP-3 AS A POTENTIAL PATHOPHYSIOLOGIC TARGET OR BIOMARKER IN CHRONIC LIVER DISEASE. 2020 5 4696 39 NF-KAPPAB REPRESSES RETINOIC ACID RECEPTOR-MEDIATED GPRC5A TRANSACTIVATION IN LUNG EPITHELIAL CELLS TO PROMOTE NEOPLASIA. CHRONIC INFLAMMATION IS ASSOCIATED WITH LUNG TUMORIGENESIS, IN WHICH NF-KAPPAB-MEDIATED EPIGENETIC REGULATION PLAYS A CRITICAL ROLE. LUNG TUMOR SUPPRESSOR G PROTEIN-COUPLED RECEPTOR, FAMILY C, MEMBER 5A (GPRC5A), IS REPRESSED IN MOST NON-SMALL CELL LUNG CANCER (NSCLC); HOWEVER, THE MECHANISMS REMAIN UNCLEAR. HERE, WE SHOW THAT NF-KAPPAB ACTS AS A TRANSCRIPTIONAL REPRESSOR IN SUPPRESSION OF GPRC5A. NF-KAPPAB INDUCED GPRC5A REPRESSION BOTH IN VITRO AND IN VIVO. INTRIGUINGLY, TRANSACTIVATION OF NF-KAPPAB DOWNSTREAM TARGETS WAS NOT REQUIRED, BUT THE TRANSACTIVATION DOMAIN OF RELA/P65 WAS REQUIRED FOR GPRC5A REPRESSION. NF-KAPPAB DID NOT BIND TO ANY POTENTIAL CIS-ELEMENT IN THE GPRC5A PROMOTER. INSTEAD, P65 WAS COMPLEXED WITH RETINOIC ACID RECEPTOR ALPHA/BETA (RARALPHA/BETA) AND RECRUITED TO THE RA RESPONSE ELEMENT SITE AT THE GPRC5A PROMOTER, RESULTING IN DISRUPTED RNA POLYMERASE II COMPLEXING AND SUPPRESSED TRANSCRIPTION. NOTABLY, PHOSPHORYLATION ON SERINE 276 OF P65 WAS REQUIRED FOR INTERACTION WITH RARALPHA/BETA AND REPRESSION OF GPRC5A. MOREOVER, NF-KAPPAB-MEDIATED EPIGENETIC REPRESSION WAS THROUGH SUPPRESSION OF ACETYLATED HISTONE H3K9 (H3K9AC), BUT NOT DNA METHYLATION OF THE CPG ISLANDS, AT THE GPRC5A PROMOTER. CONSISTENTLY, A HISTONE DEACETYLASE INHIBITOR, BUT NOT DNA METHYLATION INHIBITOR, RESTORED GPRC5A EXPRESSION IN NSCLC CELLS. THUS, NF-KAPPAB INDUCES TRANSCRIPTIONAL REPRESSION OF GPRC5A VIA A COMPLEX WITH RARALPHA/BETA AND MEDIATES EPIGENETIC REPRESSION VIA SUPPRESSION OF H3K9AC. 2023 6 6664 32 UPREGULATION OF LNCRNA71132 IN THE SPINAL CORD REGULATES HYPERSENSITIVITY IN A RAT MODEL OF BONE CANCER PAIN. BONE CANCER PAIN (BCP) IS A PERVASIVE CLINICAL SYMPTOM WHICH IMPAIRS THE QUALITY LIFE. LONG NONCODING RNAS (LNCRNAS) ARE ENRICHED IN THE CENTRAL NERVOUS SYSTEM AND PLAY INDISPENSABLE ROLES IN NUMEROUS BIOLOGICAL PROCESSES, WHILE ITS REGULATORY FUNCTION IN NOCICEPTIVE INFORMATION PROCESSING REMAINS ELUSIVE. HERE, WE REPORTED THAT FUNCTIONAL MODULATORY ROLE OF ENSRNOT00000071132 (LNCRNA71132) IN THE BCP PROCESS AND SPONGING WITH MIR-143 AND ITS DOWNSTREAM GPR85-DEPENDENT SIGNALING CASCADE. SPINAL LNCRNA71132 WAS REMARKABLY INCREASED IN THE RAT MODEL OF BONE CANCER PAIN. THE KNOCKDOWN OF SPINAL LNCRNA71132 REVERTED BCP BEHAVIORS AND SPINAL C-FOS NEURONAL SENSITIZATION. OVEREXPRESSION OF SPINAL LNCRNA71132 IN NAIVE RAT GENERATED PAIN BEHAVIORS, WHICH WERE ACCOMPANIED BY INCREASED SPINAL C-FOS NEURONAL SENSITIZATION. FURTHERMORE, IT WAS FOUND THAT LNCRNA71132 PARTICIPATES IN THE MODULATION OF BCP BY INVERSELY REGULATING THE PROCESSING OF MIR-143-5P. IN ADDITION, AN INCREASE IN EXPRESSION OF SPINAL LNCRNA71132 RESULTED IN THE DECREASE IN EXPRESSION OF MIR-143 UNDER THE BCP STATE. FINALLY, IT WAS FOUND THAT MIR-143-5P REGULATES PAIN BEHAVIORS BY TARGETING GPR85. OVEREXPRESSION OF MIR-143-5P IN THE SPINAL CORD REVERTED THE NOCICEPTIVE BEHAVIORS TRIGGERED BY BCP, ACCOMPANIED BY A DECREASE IN EXPRESSION OF SPINAL GPR85 PROTEIN, BUT NO INFLUENCE ON EXPRESSION OF GPR85 MRNA. THE FINDINGS OF THIS STUDY INDICATE THAT LNCRNA71132 WORKS AS A MIRNA SPONGE IN MIR-143-5P-MEDIATED POSTTRANSCRIPTIONAL MODULATION OF GPR85 EXPRESSION IN BCP. THEREFORE, EPIGENETIC INTERVENTIONS AGAINST LNCRNA71132 MAY POTENTIALLY WORK AS NOVEL TREATMENT AVENUES IN TREATING NOCICEPTIVE HYPERSENSITIVITY TRIGGERED BY BONE CANCER. 2023 7 4919 32 PANNEXIN-1 UP-REGULATION IN THE DORSAL ROOT GANGLION CONTRIBUTES TO NEUROPATHIC PAIN DEVELOPMENT. PANNEXIN-1 (PANX1) IS A LARGE-PORE MEMBRANE CHANNEL INVOLVED IN THE RELEASE OF ATP AND OTHER SIGNALING MEDIATORS. LITTLE IS KNOWN ABOUT THE EXPRESSION AND FUNCTIONAL ROLE OF PANX1 IN THE DORSAL ROOT GANGLION (DRG) IN THE DEVELOPMENT OF CHRONIC NEUROPATHIC PAIN. IN THIS STUDY, WE DETERMINED THE EPIGENETIC MECHANISM INVOLVED IN INCREASED PANX1 EXPRESSION IN THE DRG AFTER NERVE INJURY. SPINAL NERVE LIGATION IN RATS SIGNIFICANTLY INCREASED THE MRNA AND PROTEIN LEVELS OF PANX1 IN THE DRG BUT NOT IN THE SPINAL CORD. IMMUNOCYTOCHEMICAL LABELING SHOWED THAT PANX1 WAS PRIMARILY EXPRESSED IN A SUBSET OF MEDIUM AND LARGE DRG NEURONS IN CONTROL RATS AND THAT NERVE INJURY MARKEDLY INCREASED THE NUMBER OF PANX1-IMMUNOREACTIVE DRG NEURONS. NERVE INJURY SIGNIFICANTLY INCREASED THE ENRICHMENT OF TWO ACTIVATING HISTONE MARKS (H3K4ME2 AND H3K9AC) AND DECREASED THE OCCUPANCY OF TWO REPRESSIVE HISTONE MARKS (H3K9ME2 AND H3K27ME3) AROUND THE PROMOTER REGION OF PANX1 IN THE DRG. HOWEVER, NERVE INJURY HAD NO EFFECT ON THE DNA METHYLATION LEVEL AROUND THE PANX1 PROMOTER IN THE DRG. FURTHERMORE, INTRATHECAL INJECTION OF THE PANX1 BLOCKERS OR PANX1-SPECIFIC SIRNA SIGNIFICANTLY REDUCED PAIN HYPERSENSITIVITY INDUCED BY NERVE INJURY. IN ADDITION, SIRNA KNOCKDOWN OF PANX1 EXPRESSION IN A DRG CELL LINE SIGNIFICANTLY REDUCED CASPASE-1 RELEASE INDUCED BY NEURONAL DEPOLARIZATION. OUR FINDINGS SUGGEST THAT NERVE INJURY INCREASES PANX1 EXPRESSION LEVELS IN THE DRG THROUGH ALTERED HISTONE MODIFICATIONS. PANX1 UP-REGULATION CONTRIBUTES TO THE DEVELOPMENT OF NEUROPATHIC PAIN AND STIMULATION OF INFLAMMASOME SIGNALING. 2015 8 5838 36 STRIATAL SHATI/NAT8L-BDNF PATHWAYS DETERMINE THE SENSITIVITY TO SOCIAL DEFEAT STRESS IN MICE THROUGH EPIGENETIC REGULATION. THE GLOBAL NUMBER OF PATIENTS WITH DEPRESSION INCREASES IN CORRELATION TO EXPOSURE TO SOCIAL STRESS. CHRONIC STRESS DOES NOT TRIGGER DEPRESSION IN ALL INDIVIDUALS, AS SOME REMAIN RESILIENT. THE UNDERLYING MOLECULAR MECHANISMS THAT CONTRIBUTE TO STRESS SENSITIVITY HAVE BEEN POORLY UNDERSTOOD, ALTHOUGH REVEALING THE REGULATION OF STRESS SENSITIVITY COULD HELP DEVELOP TREATMENTS FOR DEPRESSION. WE PREVIOUSLY FOUND THAT STRIATAL SHATI/NAT8L, AN N-ACETYLTRANSFERASE, WAS INCREASED IN A DEPRESSION MOUSE MODEL. WE INVESTIGATED THE ROLES OF SHATI/NAT8L IN STRESS SENSITIVITY IN MICE AND FOUND THAT SHATI/NAT8L AND BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) LEVELS IN THE DORSAL STRIATUM WERE INCREASED IN STRESS-SUSCEPTIBLE MICE BUT NOT IN RESILIENT MICE EXPOSED TO REPEATED SOCIAL DEFEAT STRESS (RSDS). KNOCKDOWN OF SHATI/NAT8L IN THE DORSAL STRIATUM INDUCED RESILIENCE TO RSDS. IN ADDITION, BLOCKADE OF BDNF SIGNALING IN THE DORSAL STRIATUM BY ANA-12, A BDNF-SPECIFIC RECEPTOR TROPOMYOSIN-RECEPTOR-KINASE B (TRKB) INHIBITOR, ALSO INDUCED RESILIENCE TO STRESS. SHATI/NAT8L IS CORRELATED WITH BDNF EXPRESSION AFTER RSDS, AND BDNF IS DOWNSTREAM OF SHATI/NAT8L PATHWAYS IN THE DORSAL STRIATUM; SHATI/NAT8L IS EPIGENETICALLY REGULATED BY BDNF VIA HISTONE ACETYLATION. OUR RESULTS DEMONSTRATE THAT STRIATAL SHATI/NAT8L-BDNF PATHWAYS DETERMINE STRESS SENSITIVITY THROUGH EPIGENETIC REGULATION. THE STRIATAL SHATI/NAT8L-BDNF PATHWAY COULD BE A NOVEL TARGET FOR TREATMENTS OF DEPRESSION AND COULD ESTABLISH A NOVEL THERAPEUTIC STRATEGY FOR DEPRESSION PATIENTS. 2021 9 685 32 BRAIN-DERIVED NEUROTROPHIC FACTOR INVOLVED EPIGENETIC REPRESSION OF UGT2B7 IN COLORECTAL CARCINOMA: A MECHANISM TO ALTER MORPHINE GLUCURONIDATION IN TUMOR. URIDINE DIPHOSPHATE-GLUCURONOSYLTRANSFERASE (UGT) 2B7, AS ONE OF SIGNIFICANT DRUG ENZYMES, IS RESPONSIBLE ON THE GLUCURONIDATION OF ABUNDANT ENDOBIOTICS OR XENOBIOTICS. WE HERE REPORT THAT IT IS MARKEDLY REPRESSED IN THE TUMOR TISSUES OF COLORECTAL CARCINOMA (CRC) PATIENTS. ACCORDINGLY, MORPHINE IN CRC CELLS WILL STIMULATE THE EXPRESSION OF ITS MAIN METABOLIC ENZYME, UGT2B7 DURING TOLERANCE GENERATION BY ACTIVATING THE POSITIVE SIGNALS IN HISTONE 3, ESPECIALLY FOR TRIMETHYLATED LYSINE 27 (H3K4ME3) AND ACETYLATED LYSINE 4 (H3K27AC). FURTHER STUDY REVEALS THAT BRAIN-DERIVED NEUTROPHILIC FACTOR (BDNF), A SECRETORY NEUROTROPHIN, ENRICHED IN CRC CAN INTERACT AND INHIBIT UGT2B7 BY PRIMARILY BLOCKING THE POSITIVE SIGNALS OF H3K4ME3 AS WELL AS ACTIVATING H3K27AC ON THE PROMOTER REGION OF UGT2B7. MEANWHILE, BDNF REPRESSION ATTRIBUTES TO THE SENSITIZATIONS OF MAIN CORE FACTORS IN POLY-COMB REPRESSIVE COMPLEX (PRC) 1 RATHER THAN PRC2 AS THE REASON OF THE DEPRESSION OF SUZ12 IN THE LATER COMPLEX. BESIDES THAT, THE PRODUCTIONS OF TWO MAIN MORPHINE GLUCURONIDES ARE BOTH INCREASED IN THE BDNF DEFICIENT OR TSA AND BIX-01294 TREATED MORPHINE TOLERANCE-LIKE HCT-116 CELLS. ON THE SAME CONDITION, ACTIVE METABOLITE, MORPHINE-6-GLUCURONIDE (M6G) WAS ACCUMULATED MORE THAN INACTIVE M3G. OUR FINDINGS IMPLY THAT ENZYMATIC ACTIVITY ENHANCEMENT AND SUBSTRATE REGIOSELECTIVE CATALYSIS ALTERATION OF UGT2B7 MAY RELEASE MORPHINE TOLERANCE UNDER THE CURE OF TUMOR-INDUCED PAIN. 2017 10 5692 25 SILENCING OF LNCRNA PKIA-AS1 ATTENUATES SPINAL NERVE LIGATION-INDUCED NEUROPATHIC PAIN THROUGH EPIGENETIC DOWNREGULATION OF CDK6 EXPRESSION. NEUROPATHIC PAIN (NP) IS AMONG THE MOST INTRACTABLE COMORBIDITIES OF SPINAL CORD INJURY. DYSREGULATION OF NON-CODING RNAS HAS ALSO BEEN IMPLICATED IN THE DEVELOPMENT OF NEUROPATHIC PAIN. HERE, WE IDENTIFIED A NOVEL LNCRNA, PKIA-AS1, BY USING LNCRNA ARRAY ANALYSIS IN SPINAL CORD TISSUE OF SPINAL NERVE LIGATION (SNL) MODEL RATS, AND INVESTIGATED THE ROLE OF PKIA-AS1 IN SNL-MEDIATED NEUROPATHIC PAIN. WE OBSERVED THAT PKIA-AS1 WAS SIGNIFICANTLY UPREGULATED IN SNL MODEL RATS AND THAT PKIA-AS1 KNOCKDOWN ATTENUATED NEUROPATHIC PAIN PROGRESSION. ALTERNATIVELY, OVEREXPRESSION OF PKIA-AS1 WAS SUFFICIENT TO INDUCE NEUROPATHIC PAIN-LIKE SYMPTOMS IN UNINJURED RATS. WE ALSO FOUND THAT PKIA-AS1 MEDIATED SNL-INDUCED NEUROPATHIC PAIN BY DIRECTLY REGULATING THE EXPRESSION AND FUNCTION OF CDK6, WHICH IS ESSENTIAL FOR THE INITIATION AND MAINTENANCE OF NEUROINFLAMMATION AND NEUROPATHIC PAIN. THEREFORE, OUR STUDY IDENTIFIES PKIA-AS1 AS A NOVEL THERAPEUTIC TARGET FOR NEUROINFLAMMATION RELATED NEUROPATHIC PAIN. 2019 11 6148 35 THE EXPRESSION OF TRANSCRIPTION FACTORS MECP2 AND CREB IS MODULATED IN INFLAMMATORY PELVIC PAIN. EARLY ACTIVATION OF TRANSCRIPTION FACTORS IS ONE OF THE EPIGENETIC MECHANISMS CONTRIBUTING TO THE INDUCTION AND MAINTENANCE OF CHRONIC PAIN STATES. PREVIOUS STUDIES IDENTIFIED THE CHANGES IN A NUMBER OF NOCICEPTION-RELATED GENES, SUCH AS CALCITONIN GENE-RELATED PEPTIDE (CGRP), SUBSTANCE P (SP), AND BRAIN-DERIVED NEUROTROPIC FACTOR (BDNF) IN THE PELVIC ORGANS AFTER TRANSIENT COLONIC INFLAMMATION. THE GENE AND PROTEIN EXPRESSION OF THESE NEUROPEPTIDES COULD BE MODULATED BY TRANSCRIPTION FACTORS METHYL-CPG-BINDING PROTEIN 2 (MECP2) AND CAMP RESPONSE ELEMENT-BINDING PROTEIN (CREB). IN THIS STUDY, WE AIMED TO EVALUATE TIME-DEPENDENT CHANGES IN THE EXPRESSION LEVELS OF MECP2 AND CREB IN THE LUMBOSACRAL (LS) SPINAL CORD AND SENSORY GANGLIA AFTER INFLAMMATION-INDUCED PELVIC PAIN IN RAT. ADULT SPRAGUE-DAWLEY RATS WERE TREATED WITH 2,4,6-TRINITROBENZENESULFONIC ACID (TNBS) TO INDUCE TRANSIENT COLONIC INFLAMMATION. LS (L6-S2) SPINAL CORD SEGMENTS AND RESPECTIVE DORSAL ROOT GANGLIAS (DRGS) WERE ISOLATED FROM CONTROL AND EXPERIMENTAL ANIMALS AT 1, 2, 6, 24 H AND 3 DAYS POST-TNBS TREATMENT. IMMUNOHISTOCHEMICAL (IHC) LABELING AND WESTERN BLOTTING EXPERIMENTS WERE PERFORMED TO ASSESS THE EXPRESSION OF MECP2, CREB AND THEIR PHOSPHORYLATED FORMS. TOTAL MECP2 EXPRESSION, BUT NOT PHOSPHORYLATED P-MECP2 (PS421MECP2) EXPRESSION WAS DETECTED IN THE CELLS OF THE SPINAL DORSAL HORN UNDER CONTROL CONDITIONS. COLONIC INFLAMMATION TRIGGERED A SIGNIFICANT DECREASE IN THE NUMBER OF MECP2-EXPRESSING NEURONS IN PARALLEL WITH ELEVATED NUMBERS OF PS421MECP2-EXPRESSING CELLS AT 2 H AND 6 H POST-TNBS. THE MAJORITY OF MECP2-POSITIVE CELLS (80 +/- 6%) CO-EXPRESSED CREB. TNBS TREATMENT CAUSED A TRANSIENT UP-REGULATION OF CREB-EXPRESSING CELLS AT 1 H POST-TNBS ONLY. THE NUMBER OF CELLS EXPRESSING PHOSPHORYLATED CREB (PS133CREB) DID NOT CHANGE AT 1 H AND 2 H POST-TNBS, BUT WAS DOWN-REGULATED BY THREE FOLDS AT 6 H POST-TNBS. ANALYSIS OF DRG SECTIONS REVEALED THAT THE NUMBER OF MECP2-POSITIVE NEURONS WAS UP-REGULATED BY TNBS TREATMENT, REACHING THREE-FOLD INCREASE AT 2 H POST-TNBS, AND EIGHT-FOLD INCREASE AT 6 H POST-TNBS (P